CellType
ActiveThe agentic drug company. We simulate human biology.
About
CellType is building an agentic drug company. AI agents that run the full drug discovery pipeline on top of biological foundation models that simulate human biology. Our core technology, developed with Google DeepMind, has already discovered and validated a new cancer treatment signal. We’re working with Top 10 pharma.
Founders · 2
Co-Founder & CEO of CellType (W26). Yale Professor, 11,000+ citations. Built biological foundation models with Google. Building the agentic drug company.
Co-Founder @ CellType (W26). ML @ Yale & EPFL. Building the next-generation agentic drug company. Co-developed our core technology Cell2Sentence at Yale and published at ICML. Previously led large-scale foundation model training at a biotech startup and built software to control CERN's Large Hadron Collider.
Launch
What takes big pharma years, we aim to do in weeks.
A Yale-founded company builds AI-powered drug discovery with foundation models plus autonomous AI agents to run the full discovery pipeline. They offer a computational “virtual human” to predict human outcomes, enabling target discovery, toxicity and translational predictions, patient stratification, and virtual trials, aiming to de-risk and accelerate drug development for pharma/biotech teams.
Formerly “Contextual Bio”
Related startups
AI and Data for Cancer Therapeutics
The AI-native platform for next-generation protein characterization.
